ALAMEDA, Calif.--Strata Biosciences here was awarded a $100,000 Small Business Innovation Research grant from the US National Cancer Institute for a six-month functional genomics technology innovation project. Strata is a privately funded functional genomics company implementing proprietary high-throughput gene knockout technologies for gene discovery, drug target identification, and validation.
According to Douglas Lane, president and chief executive officer, Strata's technology has the capacity to validate and target genes at a rate exceeding industry standards. "These proprietary tools accelerate the most critical step of conventional pharmaceutical innovation, resulting in cost-effective drug discovery," he said.
Combining molecular biology, high-throughput screening, bioinformatics, and cell-based models, Strata's efforts are focused on research in the areas of prostate, breast, and ovarian cancer, and immune regulation.